Journals / Türk Anestezi ve Reanimasyon Dergisi / 2012 / Cilt: 40 - Sayı: 5

Effects of extracorporeal liver support systems in liver failure

Karaciğer yetersizliğinde uygulanan ekstrakorporeal destek sistemlerinin etkileri

Pages
269–273
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

All transplanted patients (n=7; MARS: 3, FPSA: 4) and 12 (30.8%) of the remaining patients without transplantation survived, obtaining an overall survival of 50%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Extracorporeal liver support systems represent an important option for the treatment of liver failure.
📊
Key Findings & Data:Methods: Molecular Absorbent Recirculating System (MARS) (10 patients) and fractionated plasma separation and adsorption (FPSA) (28 patients) were performed 114 times in 38 patients.
💡
Conclusion & Impact:All transplanted patients (n=7; MARS: 3, FPSA: 4) and 12 (30.8%) of the remaining patients without transplantation survived, obtaining an overall survival of 50%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Extracorporeal liver support systems represent an important option for the treatment of liver failure. In this retrospective study, effects of two differ- ent support systems were examined, and these systems were compared. Methods: Molecular Absorbent Recirculating System (MARS) (10 patients) and fractionated plasma separation and adsorption (FPSA) (28 patients) were performed 114 times in 38 patients. The frequencies of liver transplantation and survival; SOFA and hepatic encephalopathy scores, levels of total bilirubin, am- monia, albumin, blood urea nitrogen (BUN), creatinine and lactate, leucocyte and thrombocyte counts, as well as frequency of hemodynamic instability were investigated and compared. The method used for anticoagulation, the number of applications/patients and the length of stay in ICU were also recorded. Results: There were 3±1.8 (range: 1-7) treatments/patient. All transplanted patients (n=7; MARS: 3, FPSA: 4) and 12 (30.8%) of the remaining patients without transplantation survived, obtaining an overall survival of 50%. There was a decrease in the levels of bilirubin, BUN and creatinine with both systems; the decrease was more pronounced with FPSA. FPSA also achieved a significant decrease in ammonia level. With FPSA, there were also significant changes in albumin, leucocyte and thrombocyte counts and INR. MARS was associated with significantly less hemodynamic instability. Conclusion: Both systems have been found to be effective as a “bridge therapy” for liver transplantation, in 1/4 of the patients they can even eliminate the indi- cation for liver transplantation. Effects of FPSA on detoxification appeared to be more pronounced, whereas MARS obtained a more stable hemodynamic status during treatment.

Özet

Amaç: Ekstrakorporeal destek sistemleri, karaciğer yetersizliğinde önemli bir tedavi seçeneği sunmaktadırlar. Bu retrospektif çalışmada, iki farklı destek sis- temi ile ilgili deneyimler ışığında bu sistemlerin etkileri araştırılmış ve sistemler, birbiriyle karşılaştırılmıştır. Yöntemler: Molekül abzorbe edici resirkülasyon sistemi (MARS) (10 hasta) ve plazmadan emilim yoluyla doğrudan adzorpsiyon (FPSA) (28 hasta) sistemleri- nin uygulandığı 38 hastada, 114 işlem değerlendirilmiştir. Karaciğer nakli ve sağ- kalım sıklığı araştırılmış; SOFA ve hepatik ensefalopati skorları, total bilirübin, amonyak, albümin, kan idrar nitrojeni (BUN), kreatinin, laktat düzeyleri, INR ve lökosit ve trombosit sayıları ve ayrıca hemodinamik değişikliklerin sıklığı in- celenip karşılaştırılmıştır. Kullanılmış olan antikoagülasyon yöntemi, destek sis- teminin kaç kez uygulandığı ve hastanın yoğun bakım kalış süresi kaydedilmiştir. Bulgular: Her hastaya 3±1,8 (sınır: 1-7) seans uygulanmıştır. Nakil yapılan 7 (MARS: 3; FPSA: 4) hastanın tümü yaşamış; nakil yapılmayan hastaların 12’si (%30,8) yaşamış; genel sağkalım %50 olmuştur. Her iki sistem ile bilirübin, BUN ve kreatinin düzeylerinde düşmeler sağlanmış; FPSA ile bu düşüşler daha belirgin olmuş; ayrıca amonyak düzeyinde de anlamlı azalma görülmüştür. FPSA ile albümin, trombosit ve lökosit sayısı ile INR’de de anlamlı değişiklikler saptanmıştır. MARS ile anlamlı olarak daha az hemodinamik sorun ile karşıla- şılmıştır. Sonuç: İki sistem de, karaciğer nakline kadar vakit kazanılmasında, nakil gerçek- leşene kadar hastanın genel durumunun düzeltilmesinde, yaklaşık 1/4 hastada da karaciğer nakli endikasyonunun ortadan kaldırılmasında etkili olabilmektedir. FPSA, detoksifikasyon işleminde daha etkin görünmektedir; buna karşın MARS, bu kritik hasta grubunda, daha istikrarlı bir hemodinami sağlayabilmektedir.

🔖

Cite This Article

ORHUN, G., ESEN, F., ERGİN, P. Ö., ŞENTÜRK, E., PINARBAŞI, B., ÇAKAR, N., TELCİ, L. (2022). Effects of extracorporeal liver support systems in liver failure. Türk Anestezi ve Reanimasyon Dergisi, Cilt: 40 - Sayı: 5, 269–273. https://ajindex.com/articles/619773

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Rifai K, Tetta C, Ronco C. Liver support with fractionated Plasma sep- aration and adsorption and Prometheus®. In 2008 Yearbook of Inten- sive Care and Emergency Medicine. Edited by Vincent JL. Springer; 2008: 777-85.
  2. Stockmann H, Hiemstra CA, Marquet RL, IJzermans JN. Extracorpo- real perfusion for the treatment of acute liver failure. Ann Surg 2000, 231: 460-70. [CrossRef ] Sentürk E, Esen F, Ozcan PE, Rifai K, Pinarbaşi B, Cakar N, et al. The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications. J Clin Apher 2010; 25: 195-201. [CrossRef ] Bacher A. Extracorporeal liver support w,th multipass albümin dialysis or plasmapheresis and filtering systems in acute liver failure. Liver In- ternational 2011; 31: 16-8. [CrossRef ] 5. Şentürk E. Yoğun Bakımda Karaciğer Destek tedavisi. Türk Yoğun Bakım Derneği Dergisi 2008; 6: 25-32. 6. Bismuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver Transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996, 16: 415-25. [CrossRef ] 7. Krisper P, Staube RE. Technoly insight: artifical extracorporeal liver support- how does Prometheus compare with MARS? Nat Clin Pract Nephrol 2007; 3: 267-76. [CrossRef ] 8. Hassanein TI, Schade RR, Hepburn IS. Acute on chronic liver failure: extracorporeal liver assist devices. Current Opinion in Crit Care 2011; 17: 195-203. [CrossRef ] 9. Krisper P, Stadlbauer V, Stauber RE. Clearing of toxic substances: are there differences between the available liver support devices? Liver In- ternational 2011: 31;5-8. [CrossRef ] 10. Kramer L, Kodras K. Detoxification as a treatment goal in hepatic fail- ure. Liver Int 2011; 31: 1-4. [CrossRef ] 11. Rifai K, Ernst T, Kretschmer U, Hafer C, Haller H, Manns MP, Fliser D. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 2005, 23: 298-302. [CrossRef ] 12. Mitzner SR, Stange J, Klammt S, Koball S, Hickstein H, Reisinger EC. Albumin dialysis MARS: knowledge from 10 years of clinical investi- gation. ASAIO J 2009; 55: 498-502. [CrossRef ] 13. Krisper P, Haditsch B, Stauber R, Jung A, Stadlbauer V, Trauner M, et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005; 43: 451-7. [CrossRef ] 14. Laleman W, Wilmer A, Evenepoel P, Verslype C, Fevery J, Nevens F. Review article: non-biological liver support in liver failure. Aliment Pharmacol Th